Patent: 5,270,181

Summary for Patent: 5,270,181

Title:	Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
Abstract:	This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.
Inventor(s):	McCoy; John (Reading, MA), LaVallie; Edward R. (Tewksbury, MA)
Assignee:	Genetics Institute, Inc. (Cambridge, MA)
Application Number:	07/745,382
Patent Claims:	see list of patent claims

Details for Patent 5,270,181

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	11/25/1997		2011-02-06

International Patent Family for US Patent 5,270,181

Country	Patent Number	Estimated Expiration
Austria	237692
Austria	456661
Australia	1399495
Australia	1467192
Australia	4781493
Australia	663489